Study period | Washout | Observation | Baseline | Treatment | Follow-up | |||
---|---|---|---|---|---|---|---|---|
Timepoint | ≦7 days | 3-7 days | 0 day | 1 day* | 3 week◈ | 3 week⊙ | 1 month | 3 month |
Patients | ||||||||
Informed consent | × | |||||||
Eligibility screening | × | |||||||
Patients’essential information | × | |||||||
Allocation | × | |||||||
Primary outcome | ||||||||
sEMG | × | × | × | × | ||||
EEG | × | × | × | × | ||||
sEMG synergy-coherence analysis | × | × | × | × | ||||
EEG power spectrum analysis | × | × | × | × | ||||
Secondary outcomes | ||||||||
MBI | × | × | × | × | ||||
CSS | × | × | × | × | ||||
FMA-U | × | × | × | × | ||||
MMT | × | × | × | × | ||||
Brunnstrom | × | × | × | × | ||||
Healthy controls | ||||||||
Informed consent | × | |||||||
Eligibility screening | × | |||||||
Patients’ essential information | × | |||||||
Primary outcome | ||||||||
sEMG | × | |||||||
EEG | × | |||||||
sEMG synergy-coherence analysis | × | |||||||
EEG power spectrum analysis | × | |||||||
Blinding assessment | × | × | × | |||||
Adjuvant therapy | × | × | × | × | × | |||
Adverse events | × | × | × | × | × |